Maravai LifeSciences (MRVI) Expected to Announce Earnings on Monday

Maravai LifeSciences (NASDAQ:MRVI) is expected to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $44.01 million for the quarter.

Maravai LifeSciences Stock Down 3.9 %

Shares of NASDAQ:MRVI opened at $1.99 on Friday. The stock has a market capitalization of $506.13 million, a P/E ratio of -1.21 and a beta of 0.19. The stock’s 50-day moving average price is $2.17 and its 200-day moving average price is $4.21. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a 12-month low of $1.67 and a 12-month high of $11.56.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MRVI. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research report on Friday, March 21st. UBS Group cut their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st. Bank of America decreased their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Morgan Stanley dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, March 25th. Finally, Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $9.00 to $3.00 in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of “Hold” and a consensus price target of $6.34.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.